MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
equity securities, net
$12,559,728
Cash received from
asset acquisition,...
$1,341,735
Net cash provided by
financing activities
$12,337,862
Net cash provided by
investing activities
$764,735
Canceled cashflow
$221,866
Canceled cashflow
$577,000
Net increase
(decrease) in cash, cash...
$8,275,409
Canceled cashflow
$4,827,188
Payments on note payable
$221,866
In-process research and
development expense
$8,517,966
Prepaid expenses and
other current assets
-$419,628
Equity-based compensation
$219,058
Depreciation, amortization
and impairment
$7,151
Issuance of promissory
loan in connection...
$577,000
Net cash used in
operating activities
-$4,827,188
Canceled cashflow
$9,163,803
Net loss
-$12,518,480
Accounts payable
-$1,167,068
Accrued expenses
-$298,903
Change in fair value of
warrant liability
-$6,540
Back
Back
Cash Flow
source: myfinsight.com
Decoy Therapeutics Inc. (DCOY)
Decoy Therapeutics Inc. (DCOY)